115.10
-3.16 (-2.67%)
Market Trend
Short Term | Medium Term | ||
Industry | Diagnostics & Research (US) | Mixed | Mixed |
Diagnostics & Research (Global) | Mixed | Mixed | |
Stock | Natera, Inc. | Bullish | Bullish |
Stockmoo Score
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
Sector | Healthcare |
Industry | Diagnostics & Research |
Investment Style | Mid Growth |
52 Weeks Range | ||
Price Target Range | ||
High | 150.00 (Piper Sandler, 30.32%) | Buy |
Median | 140.00 (21.63%) | |
Low | 120.00 (Baird, 4.26%) | Buy |
Average | 137.13 (19.14%) | |
Total | 8 Buy | |
Avg. Price @ Call | 116.40 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Canaccord Genuity | 27 Aug 2024 | 145.00 (25.98%) | Buy | 120.27 |
Morgan Stanley | 13 Aug 2024 | 132.00 (14.68%) | Buy | 119.02 |
Piper Sandler | 13 Aug 2024 | 150.00 (30.32%) | Buy | 119.02 |
BTIG | 09 Aug 2024 | 135.00 (17.29%) | Buy | 114.57 |
Baird | 09 Aug 2024 | 120.00 (4.26%) | Buy | 114.57 |
Stephens & Co. | 09 Aug 2024 | 125.00 (8.60%) | Buy | 114.57 |
TD Cowen | 09 Aug 2024 | 145.00 (25.98%) | Buy | 114.57 |
UBS | 09 Aug 2024 | 145.00 (25.98%) | Buy | 114.57 |
No data within this time range.
Date | Type | Details |
---|---|---|
28 Aug 2024 | Announcement | Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
08 Aug 2024 | Announcement | Natera Reports Second Quarter 2024 Financial Results |
06 Aug 2024 | Announcement | Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference |
30 Jul 2024 | Announcement | Natera to Report its Second Quarter 2024 Results on August 8, 2024 |
26 Jul 2024 | Announcement | New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma |
03 Jul 2024 | Announcement | Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy |
27 Jun 2024 | Announcement | Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer |
17 Jun 2024 | Announcement | Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |